Destiny Pharma Conference Attendance for May 2021
Thursday May 6, 2021
Thursday May 6, 2021
Destiny Pharma plc
(“Destiny Pharma” or the “Company”)
Destiny Pharma Conference Attendance for May 2021
Brighton, United Kingdom – 6th May 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that its management team will be presenting and participating at the following conferences:
Proactive One2One Virtual Forum – Thursday 6th May 2021 at 7:00pm BST
Neil Clark, CEO will present at this virtual event, hosted by Proactive Investors.
Destiny Pharma has been invited to present as a ‘Leading Growth Company’ to provide an overview of the Company and its innovative pipeline.
BioEquity Europe – Tuesday 18th May 2021
William Love, Founder and CSO will present and participate in “What is the Next Act for Antibiotics?” panel discussion.
The distinguished panel entitled “What is the Next Act for Antibiotics” includes investors and antibiotics leaders, such as Destiny Pharma, who will discuss and identify the requirements for new mechanisms to incentivize the next act of antibiotics investment and development. The Panel, chaired by Steve Usdin, Senior Editor & Head Policy and Regulation, BioCentury, includes:
In addition to the panel discussion, Destiny Pharma will also be presenting to potential partners and investors in attendance.
If you would like to virtually meet with Destiny Pharma, please email us on conferences@destinypharma.com
Enquiries:
| Destiny Pharma plc | +44 (0) 12 7370 4440 |
| Neil Clark (Chief Executive Officer) Shaun Claydon (Chief Financial Officer and Company Secretary) |
|
Optimum Strategic Communications |
+44 (0) 20 3174 1789 |
| Mary Clark / Shabnam Bashir / Manel Mateus |
About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infections in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.
For further information on the Company, please visit www.destinypharma.com